Skye Bioscience, Inc. Common Stock (SKYE) - Total Liabilities
Based on the latest financial reports, Skye Bioscience, Inc. Common Stock (SKYE) has total liabilities worth $8.29 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Skye Bioscience, Inc. Common Stock generate cash to assess how effectively this company generates cash.
Skye Bioscience, Inc. Common Stock - Total Liabilities Trend (2012–2025)
This chart illustrates how Skye Bioscience, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check SKYE asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Skye Bioscience, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Skye Bioscience, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Star Paper Mills Limited
NSE:STARPAPER
|
India | Rs1.45 Billion |
|
Sogn Sparebank
OL:SOGN
|
Norway | Nkr7.03 Billion |
|
Nexted Group Ltd
AU:NXD
|
Australia | AU$97.66 Million |
|
PC Direct Inc
KQ:051380
|
Korea | ₩61.56 Billion |
|
Fiplasto SA
BA:FIPL
|
Argentina | AR$62.74 Billion |
|
Hultström Group B
ST:HULT-B
|
Sweden | Skr58.74 Million |
|
Wealth Minerals Ltd.
V:WML
|
Canada | CA$447.12K |
Liability Composition Analysis (2012–2025)
This chart breaks down Skye Bioscience, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Skye Bioscience, Inc. Common Stock.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Skye Bioscience, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Skye Bioscience, Inc. Common Stock (2012–2025)
The table below shows the annual total liabilities of Skye Bioscience, Inc. Common Stock from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $8.29 Million | +79.73% |
| 2024-12-31 | $4.61 Million | -67.23% |
| 2023-12-31 | $14.07 Million | +16.12% |
| 2022-12-31 | $12.12 Million | +203.67% |
| 2021-12-31 | $3.99 Million | +79.70% |
| 2020-12-31 | $2.22 Million | +53.31% |
| 2019-12-31 | $1.45 Million | -91.73% |
| 2018-12-31 | $17.52 Million | +1190.76% |
| 2017-12-31 | $1.36 Million | -23.50% |
| 2016-12-31 | $1.77 Million | -41.64% |
| 2015-12-31 | $3.04 Million | +279.11% |
| 2014-12-31 | $801.89K | +340.23% |
| 2013-12-31 | $182.15K | +4111.63% |
| 2012-12-31 | $4.33K | -- |
About Skye Bioscience, Inc. Common Stock
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company wa… Read more